1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181132, NCT00706706
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181177, NCT00793871
|
|
3.
|
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181181, NCT00836745
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181185, NCT00873210
|
|
5.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P070104, NCT00930345
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181034, NCT00083889
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181036, NCT00094029
|
|
8.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2805, E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181109, NCT00375674
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181064, NCT00393939
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181107, NCT00373113
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181114, NCT00428220
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181087, SUN1087, NCT00457392
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181122, NCT00457691
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181120, NCT00676650
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061032, AXIS TRIAL, NCT00678392
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-30607, CALGB 30607, NCT00693992
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181170, NCT00699374
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 108844, NCT00720941
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 09072008-13772, EudraCT 2008-005011-18, NCT00732914
|
|
21.
|
Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SUIR8687, NCT00869011
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P070144, NCT00930033
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181043, NCT00137436
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-30504, CALGB 30504, NCT00453154
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 06-0906, NCT00463060
|
